Avalon Globocare (OTCMKTS: AVCO) is one of 26 publicly-traded companies in the “Management consulting services” industry, but how does it weigh in compared to its competitors? We will compare Avalon Globocare to similar businesses based on the strength of its profitability, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings.
This table compares Avalon Globocare and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Avalon Globocare Competitors||-16.11%||-37.26%||-2.64%|
This table compares Avalon Globocare and its competitors revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Avalon Globocare||$1.08 million||-$3.46 million||N/A|
|Avalon Globocare Competitors||$993.84 million||$66.10 million||20.79|
Avalon Globocare’s competitors have higher revenue and earnings than Avalon Globocare.
This is a breakdown of current ratings for Avalon Globocare and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Avalon Globocare Competitors||123||406||581||30||2.45|
As a group, “Management consulting services” companies have a potential upside of 10.60%. Given Avalon Globocare’s competitors higher probable upside, analysts plainly believe Avalon Globocare has less favorable growth aspects than its competitors.
Insider and Institutional Ownership
65.4% of shares of all “Management consulting services” companies are held by institutional investors. 75.0% of Avalon Globocare shares are held by company insiders. Comparatively, 13.3% of shares of all “Management consulting services” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Volatility and Risk
Avalon Globocare has a beta of -2.03, meaning that its stock price is 303% less volatile than the S&P 500. Comparatively, Avalon Globocare’s competitors have a beta of 0.80, meaning that their average stock price is 20% less volatile than the S&P 500.
Avalon Globocare competitors beat Avalon Globocare on 8 of the 9 factors compared.
Avalon Globocare Company Profile
Avalon GloboCare Corp., together with its subsidiaries, engages in integrating and managing healthcare services and resources in the United States. It provides medical related consulting services and develops Avalon Cell and Avalon Rehab platforms that cover the areas of regenerative medicine, cell-based immunotherapy, and exosome technology, as well as rehabilitation medicine. The company also develops proprietary diagnostic and therapeutic products leveraging exosome technology; and markets and distributes proprietary exosome isolation systems and related products to hospitals, as well as provides development services for hospitals. In addition, it owns and operates real property. The company has a strategic partnership Weill Cornell Medical College to co-develop technologies and bio-production of chimeric antigen receptor-T Therapy. Avalon GloboCare Corp. is headquartered in Freehold, New Jersey.
Receive News & Ratings for Avalon Globocare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalon Globocare and related companies with MarketBeat.com's FREE daily email newsletter.